Dr Matthew Murray
- Position: Visitor (unpaid)
- Email: M.J.Murray@leeds.ac.uk
- Phone: +44(0)113 343 8592
Dr Murray has research experience in the areas of pulsed laser ablation, deposition and implantation, photovoltaics, photonics integration, spectroscopy, glass technology and semiconductor physics. Specifically, he is focussed on the application areas of photonics integration, glass toughening, novel anti-counterfeiting solutions, biosensors, energy harvesting and other novel material/photonic engineering applications.
Presently, Dr Murray is involved in the Photonic Materials and Devices group here at Leeds, where he utilises their patented breakthrough technology: Ultrafast Laser Plasma Implantation (ULPI) for the aforementioned application areas. Dr Murray is currently developing his spin out company Ultramatis, for which he won the Royal Academy of Engineering-ERA foundation Entrepreneurial award 2015 Through this, he has developed tremendous skills and knowledge on commercialising technologies, and takes an entrepreneurial stance on all his research, guiding it as application driven.
Dr Murray also co-supervises PhD students in the areas of photonic integrated circuits and a novel glucose biosensor which is spun-out as Glucosense Diagnostics. Dr Murray and a colleague also received second place in the Royal Society of Chemistry’s Emerging Technologies Award 2015 (Materials section) for their work in using ULPI for creating advanced data communications systems to aid in big data, the internet of things and Industry 4.0.
He co-authored two successful EPSRC grants recently which his group leader, Prof Gin Jose, where £2.5mil is being utilised for the aforementioned data communications and integrated photonics systems, entitled SeaMatics, joint with world leading groups at the Universities of Sheffield, York and Cambridge as well as £1.4mil for building a pilot manufacturing facility at the University of Leeds for developing the ULPI technology. Dr Murray is currently funded by impact acceleration funding and investment to Ultramatis.